Axel Bolte M.B.A.
Axel Bolte, M.B.A., serves as an Investment Advisor of the Private Equity Team at HBM Partners Ltd. and HBM BioVentures AG, based in Zurich, Switzerland. He has nine years' experience in healthcare venture capital. Mr. Bolte previously worked as an investment manager for Swiss venture capital company NMT New Medical Technologies AG, as well as a scientist at Serono SA, where he held a position in R&D management.
He currently serves or has served on the board of directors of several biotechnology companies, including Newron Pharmaceuticals SpA, Nabriva Therapeutics AG, PTC Therapeutics, Inc., MPex Pharmaceuticals, Inc., Lux Biosciences, Inc. and Kolltan Pharmaceuticals, Inc.
Mr. Bolte received a Master of Business Administration (M.B.A.) degree from the University of St. Gallen, Switzerland and a degree in biochemistry from the Swiss Federal Institute of Technology in Zurich, Switzerland.